Rekah Financial Statements From 2010 to 2024
| REKA Stock | ILA 1,348 78.00 6.14% |
Check Rekah Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rekah main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Rekah financial statements analysis is a perfect complement when working with Rekah Pharmaceutical Valuation or Volatility modules.
Rekah |
Rekah Pharmaceutical Industry Company Return On Equity Analysis
Rekah Pharmaceutical's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Rekah Pharmaceutical Return On Equity | 0.0222 |
Most of Rekah Pharmaceutical's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rekah Pharmaceutical Industry is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Rekah Pharmaceutical Industry has a Return On Equity of 0.0222. This is 100.09% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all Israel stocks is 107.16% lower than that of the firm.
Rekah Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Rekah Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Rekah Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rekah Pharmaceutical competition to find correlations between indicators driving Rekah Pharmaceutical's intrinsic value. More Info.Rekah Pharmaceutical Industry is currently regarded as top stock in return on equity category among related companies. It is currently regarded as top stock in return on asset category among related companies reporting about 0.94 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Rekah Pharmaceutical Industry is roughly 1.07 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Rekah Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Rekah Pharmaceutical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Rekah Pharmaceutical's earnings, one of the primary drivers of an investment's value.About Rekah Pharmaceutical Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Rekah Pharmaceutical income statement, its balance sheet, and the statement of cash flows. Rekah Pharmaceutical investors use historical funamental indicators, such as Rekah Pharmaceutical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Rekah Pharmaceutical investors may use each financial statement separately, they are all related. The changes in Rekah Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Rekah Pharmaceutical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Rekah Pharmaceutical Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Rekah Pharmaceutical. Please read more on our technical analysis and fundamental analysis pages.
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company was founded in 1941 and is based in Holon, Israel. REKAH PHARMA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people.
Currently Active Assets on Macroaxis
Check out the analysis of Rekah Pharmaceutical Correlation against competitors. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Rekah Stock analysis
When running Rekah Pharmaceutical's price analysis, check to measure Rekah Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rekah Pharmaceutical is operating at the current time. Most of Rekah Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Rekah Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rekah Pharmaceutical's price. Additionally, you may evaluate how the addition of Rekah Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |